文献速递炎症性肠病

网络荟萃分析:生物制剂与小分子药物在中重度活动性腔内型克罗恩病早期起效的比较

Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-06-11

该网络荟萃分析纳入25项随机对照试验共7414例患者,比较中重度活动性腔内型克罗恩病先进疗法在治疗6周内诱导临床缓解和临床应答的早期效果。英夫利西单抗联合硫唑嘌呤或单药在6周内诱导临床缓解排名最高,显著优于塞妥珠单抗、乌司奴单抗、古塞奇尤单抗、维得利珠单抗和乌帕替尼,但对瑞莎珠单抗600 mg和阿达木单抗160/80 mg的优势未达统计学显著。在生物制剂经治患者中,乌帕替尼和瑞莎珠单抗诱导的临床应答最高。

要点

  • 英夫利西单抗联合硫唑嘌呤或单药在6周内诱导临床缓解排名最高。
  • 英夫利西单抗对瑞莎珠单抗600 mg和阿达木单抗160/80 mg的优势未达统计学显著。
  • 生物制剂经治患者中乌帕替尼和瑞莎珠单抗诱导的临床应答最高,但该人群未研究英夫利西单抗。

核心结论

  • 英夫利西单抗排名最高,除瑞莎珠单抗和阿达木单抗外优于所有其他药物,显示早期诱导缓解概率最高。
  • 在生物制剂经治患者中,乌帕替尼和瑞莎珠单抗诱导的临床应答最高,但该人群未研究英夫利西单抗。

研究设计与样本

  • 系统检索MEDLINE、Embase和CENTRAL截至2024年2月19日的随机对照试验,遵循PRISMA-NMA指南进行贝叶斯随机效应网络荟萃分析(PROSPERO ID: CRD42022368509)。
  • 共纳入25项研究、7414例患者。

主要发现

  • 共同主要结局为治疗6周内诱导临床缓解(克罗恩病活动指数CDAI≤150)和临床应答(CDAI下降≥100分)。
  • 英夫利西单抗联合硫唑嘌呤或单药在6周内诱导临床缓解排名最高,显著优于塞妥珠单抗、乌司奴单抗、古塞奇尤单抗、维得利珠单抗和乌帕替尼。
  • 英夫利西单抗对瑞莎珠单抗600 mg和阿达木单抗160/80 mg的优势未达统计学显著。
  • 在临床应答分析中,英夫利西单抗联合硫唑嘌呤和古塞奇尤单抗600 mg排名最高,但无统计学显著性。
  • 在生物制剂经治患者中,乌帕替尼和瑞莎珠单抗诱导的临床应答最高;维得利珠单抗、塞妥珠单抗和乌司奴单抗在各分析中排名最低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Rapidity of effect of advanced therapies for patients with Crohn's disease (CD) can be an essential decision parameter; however, comparative evaluation is lacking. We aimed to compare early response for advanced CD therapies in a network meta-analysis (NMA). METHODS: We searched systematically MEDLINE, Embase, and CENTRAL up to 19 February 2024, for randomised controlled trials. The co-primary outcomes were induction of clinical remission (Crohn's Disease Activity Index (CDAI) ≤150) and clinical response (≥100-point reduction in CDAI) within the first 6 weeks of treatment. We incorporated any assessment within this time point in a Bayesian random-effects NMA following PRISMA-NMA guidance (PROSPERO ID: CRD42022368509). RESULTS: Twenty-five studies, comprising 7414 patients, were included. Infliximab combined with azathioprine or monotherapy ranked highest for induction of clinical remission within 6 weeks and was significantly superior to certolizumab, ustekinumab, guselkumab, vedolizumab, and upadacitinib. However, superiority over risankizumab 600 mg and adalimumab 160/80 mg was non-significant. Accordingly, infliximab in combination with azathioprine and guselkumab 600 mg ranked highest in the corresponding analysis of clinical response with no statistical significance demonstrated. Among bio-exposed patients, none of whom received infliximab, upadacitinib, and risankizumab induced the highest clinical responses. On the other hand, vedolizumab, certolizumab, and ustekinumab ranked lowest across the analyses. CONCLUSIONS: We found infliximab to be ranked highest and superior to all other agents but risankizumab and adalimumab, demonstrating the highest probability of early induction of remission. Upadacitinib and risankizumab induced the highest clinical responses in bio-exposed patients. However, infliximab was not investigated in this population.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Attauabi M, Steenholdt C, Poulsen A, et al. Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease. Aliment Pharmacol Ther. 2024. PMID: 38863153. doi:10.1111/apt.18110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。